CTAP101

OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing industry-leading positions in large, rapidly growing markets. The company's pharmaceutical business includes Rayaldee (calcifediol), an FDA-approved treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. OPKO also maintains a robust pipeline of clinical-stage candidates, including long-acting biologics and specialized small molecules. Additionally, the company operates BioReference Laboratories, one of the largest full-service clinical laboratories in the United States, providing advanced diagnostic services.